Stockreport

Acer Therapeutics Announces Full Enrollment of Part B in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders

Acer Therapeutics Inc.  (ACER) 
Last acer therapeutics inc. earnings: 3/18 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: acertx.com/investor-relations
PDF Part A Successfully Completed and Optimal Formulation of ACER-001 Identified  Results of Part B Expected in Q1 2020 with a Planned NDA Submission in Q1 2021 NEWTON [Read more]